Amgen Expects Cinacalcet Phase IIIb Trials To Increase Physician Awareness

Amgen is trying to increase physician awareness of the hyperparathyroidism agent cinacalcet prior to launch by conducting Phase IIIb studies, Exec VP-Global Commercial Operations George Morrow said